다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Stem cells<SUP>®</SUP>, v.24 no.5, 2006년, pp.1174 - 1184
Parcells, Bertrand W. (Division of Hematology) , Ikeda, Alan K. (Division of Hematology) , Simms-Waldrip, Tiffany (Division of Hematology) , Moore, Theodore B. (Division of Hematology) , Sakamoto, Kathleen M. (Division of Hematology)
AI-Helper
AbstractLigand-mediated activation of the FMS-like tyrosine kinase 3 (FLT3) receptor is important for normal proliferation of primitive hematopoietic cells. However, activating mutations in FLT3 induce ligand-independent downstream signaling that promotes oncogenesis through pathways involved in pro...
Blood Ogawa 81 2844 1993 10.1182/blood.V81.11.2844.2844 Differentiation and proliferation of hematopoietic stem cells
Blood Metcalf 82 3515 1993 10.1182/blood.V82.12.3515.3515 Hematopoietic regulators: Redundancy or subtlety?
Blood Shivdasani 87 4025 1996 10.1182/blood.V87.10.4025.bloodjournal87104025 The transcriptional control of hematopoiesis
Oncogene Zhu 21 3295 2002 10.1038/sj.onc.1205318 Hematopoietic cytokines, transcription factors and lineage commitment
Blood Lyman 91 1101 1998 10.1182/blood.V91.4.1101 c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities
Nature Hannum 368 643 1994 10.1038/368643a0 Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs
Blood Lyman 83 2795 1994 10.1182/blood.V83.10.2795.2795 Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells
Cell Lyman 75 1157 1993 10.1016/0092-8674(93)90325-K Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells
Blood Zheng 103 267 2004 10.1182/blood-2003-06-1969 FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells
Blood Chklovskaia 93 2595 1999 10.1182/blood.V93.8.2595 Mechanism of flt3 ligand expression in bone marrow failure: Translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis
News Physiol Sci Wodnar-Filipowicz 18 247 2003 Flt3 ligand: Role in control of hematopoietic and immune functions of the bone marrow
Cell Mathews 65 973 1991 10.1016/0092-8674(91)90549-E Expression cloning of an activin receptor, a predicted transmembrane serine kinase
Genomics Rosnet 9 380 1991 10.1016/0888-7543(91)90270-O Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene
Blood Rosnet 82 1110 1993 10.1182/blood.V82.4.1110.1110 Human FLT3/FLK2 gene: CDNA cloning and expression in hematopoietic cells
Proc Natl Acad Sci U S A Small 91 459 1994 10.1073/pnas.91.2.459 STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells
Br J Haematol Abu-Duhier 113 1076 2001 10.1046/j.1365-2141.2001.02821.x Genomic structure of human FLT3: Implications for mutational analysis
Gene Agnes 145 283 1994 10.1016/0378-1119(94)90021-3 Genomic structure of the downstream part of the human FLT3 gene: Exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III
Cytogenet Cell Genet Carow 70 255 1995 10.1159/000134046 Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12->q13
Oncogene Lyman 8 815 1993 Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene
Blood Carow 87 1089 1996 10.1182/blood.V87.3.1089.bloodjournal8731089 Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias
Oncogene Rosnet 6 1641 1991 Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family
Cell Adolfsson 121 295 2005 10.1016/j.cell.2005.02.013 Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential: A revised road map for adult blood lineage commitment
Immunity Adolfsson 15 659 2001 10.1016/S1074-7613(01)00220-5 Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity
Proc Natl Acad Sci U S A Christensen 98 14541 2001 10.1073/pnas.261562798 Flk-2 is a marker in hematopoietic stem cell differentiation: A simple method to isolate long-term stem cells
Blood Ebihara 90 4363 1997 10.1182/blood.V90.11.4363 Synergistic action of Flt3 and gp130 signalings in human hematopoiesis
Int J Hematol Lyman 62 63 1995 10.1016/0925-5710(95)00389-A Biology of flt3 ligand and receptor
Stem Cells Lyman 12 (suppl 1) 99-107; discussion 108-110 1994 The flt3 ligand: A hematopoietic stem cell factor whose activities are distinct from steel factor
Eur J Immunol Ray 26 1504 1996 10.1002/eji.1830260715 Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7
Blood Rusten 87 1317 1996 10.1182/blood.V87.4.1317.bloodjournal8741317 The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro
Blood Brasel 88 2004 1996 10.1182/blood.V88.6.2004.bloodjournal8862004 Hematologic effects of flt3 ligand in vivo in mice
Blood McKenna 95 3489 2000 10.1182/blood.V95.11.3489 Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells
J Exp Med Maraskovsky 184 1953 1996 10.1084/jem.184.5.1953 Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
J Exp Med Saunders 184 2185 1996 10.1084/jem.184.6.2185 Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte/ macrophage colony-stimulating factor
Blood Maraskovsky 96 878 2000 10.1182/blood.V96.3.878 In vivo generation of human dendritic cell subsets by Flt3 ligand
Cancer Res Chakravarty 59 6028 1999 Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer
Cancer Res Chen 57 3511 1997 Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model
Nat Med Lynch 3 625 1997 10.1038/nm0697-625 Flt3 ligand induces tumor regression and antitumor immune responses in vivo
Blood Pawlowska 97 1474 2001 10.1182/blood.V97.5.1474 In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice
Mol Cell Griffith 13 169 2004 10.1016/S1097-2765(03)00505-7 The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
Mol Cell Biol Dosil 13 6572 1993 Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells
Oncogene Rottapel 9 1755 1994 Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase
J Exp Med Zhang 192 719 2000 10.1084/jem.192.5.719 Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling
Leukemia Marchetto 13 1374 1999 10.1038/sj.leu.2401527 SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor
Immunity Mackarehtschian 3 147 1995 10.1016/1074-7613(95)90167-1 Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors
Blood Birg 80 2584 1992 10.1182/blood.V80.10.2584.2584 Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
Leuk Lymphoma Birg 13 223 1994 10.3109/10428199409056285 The expression of FMS, KIT and FLT3 in hematopoietic malignancies
Leukemia Levis 17 1738 2003 10.1038/sj.leu.2403099 FLT3: ITDoes matter in leukemia
Blood Kottaridis 98 1752 2001 10.1182/blood.V98.6.1752 The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
Haematologica Moreno 88 19 2003 Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia
Leukemia Nakao 10 1911 1996 Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
Blood Schnittger 100 59 2002 10.1182/blood.V100.1.59 Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
J Mol Biol Chia 186 679 1985 10.1016/0022-2836(85)90388-2 Mutation of the Adh gene of Drosophila melanogaster containing an internal tandem duplication
Leukemia Kiyoi 12 1333 1998 10.1038/sj.leu.2401130 Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
Br J Haematol Abu-Duhier 111 190 2000 FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
Leukemia Iwai 13 38 1999 10.1038/sj.leu.2401241 Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan
Blood Kiyoi 93 3074 1999 Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
Leukemia Kiyoi 11 1447 1997 10.1038/sj.leu.2400756 Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)
Med Pediatr Oncol Kondo 33 525 1999 10.1002/(SICI)1096-911X(199912)33:6<525::AID-MPO1>3.0.CO;2-8 Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia
Leukemia Yokota 11 1605 1997 10.1038/sj.leu.2400812 Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines
Cell Wybenga-Groot 106 745 2001 10.1016/S0092-8674(01)00496-2 Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region
Mol Cell Biol Chan 23 3067 2003 10.1128/MCB.23.9.3067-3078.2003 Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region
J Biol Chem Irusta 277 38627 2002 10.1074/jbc.M204890200 Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor
J Invest Dermatol Ma 112 165 1999 10.1046/j.1523-1747.1999.00488.x Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms
Leukemia Birkenkamp 15 1923 2001 10.1038/sj.leu.2402317 Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts
Br J Haematol Fenski 108 322 2000 10.1046/j.1365-2141.2000.01831.x Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells
Leukemia Tse 16 2027 2002 10.1038/sj.leu.2402674 Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
Blood Jiang 104 1855 2004 10.1182/blood-2004-02-0712 Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML
Blood Thiede 99 4326 2002 10.1182/blood.V99.12.4326 Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis
Blood Yamamoto 97 2434 2001 10.1182/blood.V97.8.2434 Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
J Clin Invest Furitsu 92 1736 1993 10.1172/JCI116761 Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
Science Santoro 267 381 1995 10.1126/science.7824936 Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
J Biol Chem Till 276 10049 2001 10.1074/jbc.M010161200 Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: Insights into kinase mechanism
Oncogene Hayakawa 19 624 2000 10.1038/sj.onc.1203354 Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
Blood Mizuki 96 3907 2000 10.1182/blood.V96.12.3907 Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
Oncogene Scheijen 23 3338 2004 10.1038/sj.onc.1207456 FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins
Cancer Res Brandts 65 9643 2005 10.1158/0008-5472.CAN-05-0422 Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation
EMBO J Skorski 16 6151 1997 10.1093/emboj/16.20.6151 Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
Blood Levis 99 3885 2002 10.1182/blood.V99.11.3885 A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
Leukemia Tse 14 1766 2000 10.1038/sj.leu.2401905 Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation
Blood Kim 105 1759 2005 10.1182/blood-2004-05-2006 Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival
Blood Kelly 99 310 2002 10.1182/blood.V99.1.310 FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
Blood Zheng 103 1883 2004 10.1182/blood-2003-06-1978 Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression
Blood Schwable 105 2107 2005 10.1182/blood-2004-03-0940 RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation
J Biol Chem Chen 280 5361 2005 10.1074/jbc.M411974200 FLT3/ITD mutation signaling includes suppression of SHP-1
Proc Natl Acad Sci U S A Kelly 99 8283 2002 10.1073/pnas.122233699 PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model
Leukemia Lumkul 16 1818 2002 10.1038/sj.leu.2402632 Human AML cells in NOD/SCID mice: Engraftment potential and gene expression
Leukemia Yanada 19 1345 2005 10.1038/sj.leu.2403838 Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis
Blood Meshinchi 97 89 2001 10.1182/blood.V97.1.89 Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
Leukemia Xu 14 945 2000 10.1038/sj.leu.2401760 Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group
Br J Haematol Xu 105 155 1999 10.1111/j.1365-2141.1999.01284.x Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children
Leukemia Boissel 16 1699 2002 10.1038/sj.leu.2402622 Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy
Blood Frohling 100 4372 2002 10.1182/blood-2002-05-1440 Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm
Leukemia Jilani 17 114 2003 10.1038/sj.leu.2402743 Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA
Leukemia Rombouts 14 675 2000 10.1038/sj.leu.2401731 Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene
Ann Hematol Strout 78 251 1999 10.1007/s002770050511 Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: Biology and clinical implications
Br J Haematol Olesen 131 457 2005 10.1111/j.1365-2141.2005.05791.x Molecular typing of adult acute myeloid leukaemia: Significance of translocations, tandem duplications, methylation, and selective gene expression profiling
Leukemia Taki 10 1303 1996 Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia
J Clin Oncol Marcucci 23 9234 2005 10.1200/JCO.2005.03.6137 Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study
Oncogene Plass 18 3159 1999 10.1038/sj.onc.1202651 Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene
Br J Haematol Reilly 116 744 2002 10.1046/j.0007-1048.2001.03294.x Class III receptor tyrosine kinases: Role in leukaemogenesis
Leuk Res Beran 28 547 2004 10.1016/j.leukres.2003.09.016 FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype
Hematol J Chillon 5 239 2004 10.1038/sj.thj.6200382 FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor
Hematol J Sheikhha 4 41 2003 10.1038/sj.thj.6200224 Prognostic significance of FLT3 ITD and D835 mutations in AML patients
Blood Libura 102 2198 2003 10.1182/blood-2003-01-0162 FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress
N Engl J Med Druker 344 1031 2001 10.1056/NEJM200104053441401 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
Curr Pharm Des Levis 10 1183 2004 10.2174/1381612043452604 Small molecule FLT3 tyrosine kinase inhibitors
Blood Levis 98 885 2001 10.1182/blood.V98.3.885 A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
Leukemia Tse 15 1001 2001 10.1038/sj.leu.2402199 Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
Eur J Cancer Brown 40 :707 2004 10.1016/j.ejca.2003.08.030 FLT3 inhibitors: A paradigm for the development of targeted therapeutics for paediatric cancer
Cancer Res Fong 59 99 1999 SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
Clin Cancer Res Mendel 6 4848 2000 The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
Blood Smolich 97 1413 2001 10.1182/blood.V97.5.1413 The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
J Pharm Pharmacol Sukbuntherng 53 1629 2001 10.1211/0022357011778232 Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416
Blood Yee 100 2941 2002 10.1182/blood-2002-02-0531 SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase
Blood Spiekermann 101 1494 2003 10.1182/blood-2002-04-1045 The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3
Blood Giles 102 795 2003 10.1182/blood-2002-10-3023 SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Blood Fiedler 102 2763 2003 10.1182/blood-2002-10-2998 A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
Cancer Giles 97 1920 2003 10.1002/cncr.11315 Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor-in patients with refractory myeloproliferative diseases
Curr Opin Hematol Levis 12 55 2005 10.1097/01.moh.0000148761.23036.e6 Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia
Cancer Cell Weisberg 1 433 2002 10.1016/S1535-6108(02)00069-7 Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
Blood Stone 105 54 2005 10.1182/blood-2004-03-0891 Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
Clin Cancer Res Mendel 9 327 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
Blood O'Farrell 101 3597 2003 10.1182/blood-2002-07-2307 SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
Clin Cancer Res O'Farrell 9 5465 2003 An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients
Cancer Cell Kelly 1 421 2002 10.1016/S1535-6108(02)00070-3 CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Blood Corbin 104 3754 2004 10.1182/blood-2004-06-2189 Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970
J Med Chem Pandey 45 3772 2002 10.1021/jm020143r Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family
J Pharmacol Exp Ther Yu 298 1172 2001 Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury
Blood Heinrich 96 925 2000 10.1182/blood.V96.3.925 Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
Cancer Res George 59 2395 1999 Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)
Blood Zheng 100 4154 2002 10.1182/blood-2002-03-0936 Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations
Blood Smith 103 3669 2004 10.1182/blood-2003-11-3775 Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
Leukemia Komeno 19 930 2005 10.1038/sj.leu.2403736 Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase
Proc Natl Acad Sci U S A Komarova 102 9714 2005 10.1073/pnas.0501870102 Drug resistance in cancer: Principles of emergence and prevention
Science Gorre 293 876 2001 10.1126/science.1062538 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
Leukemia Hochhaus 16 2190 2002 10.1038/sj.leu.2402741 Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Science Schindler 289 1938 2000 10.1126/science.289.5486.1938 Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
N Engl J Med Druker 344 1038 2001 10.1056/NEJM200104053441402 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
Blood Clark 104 2867 2004 10.1182/blood-2003-12-4446 Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518
Blood Grundler 102 646 2003 10.1182/blood-2002-11-3441 Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor
Blood Bagrintseva 103 2266 2004 10.1182/blood-2003-05-1653 Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells
Cancer Res Cools 64 6385 2004 10.1158/0008-5472.CAN-04-2148 Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia
Blood Sohal 101 3188 2003 10.1182/blood-2002-06-1800 A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657
Proc Natl Acad Sci U S A Mohi 101 3130 2004 10.1073/pnas.0400063101 Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs
Blood Levis 104 1145 2004 10.1182/blood-2004-01-0388 In vitro studies of a FLT3 inhibitor combined with chemotherapy: Sequence of administration is important to achieve synergistic cytotoxic effects
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.